News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase I (World)
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014
TiGenix Starts Phase I Trial Of Cx611 In Severe Sepsis 12/10/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology 12/8/2014
VAXIMM Reports Positive Follow-On Data From Oral Cancer Vaccine Trial 12/4/2014
Bavarian Nordic (BAVA.CO) Announces First Subject Dosed With Mva-Bn Filo In A Phase 1 Study Investigating A New Prime-Boost Regimen Of Ebola Candidate Vaccines 12/4/2014
Rhizen Pharmaceuticals S.A. To Present Phase 1 Clinical And Additional Preclinical Data Of RP6530 (Dual PI3K Delta/Gamma Inhibitor) In Hematological Malignancies 12/3/2014
CollPlant Launched A Clinical Trial With VergenixFG; A Gel Based On A Human Collagen For The Treatment Of Chronic Wounds 12/2/2014
AstraZeneca PLC (AZN) And Eli Lilly (LLY) Move Alzheimer's Drug Into Big Trial 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
ABIVAX Successfully Completes First-In-Man Study Of ABX464, A Highly Differentiated Small Molecule Targeting HIV 12/1/2014
GlaxoSmithKline (GSK), NIH Report Positive Ebola Vaccine Phase 1 Trial 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 11/26/2014
Synthon Initiates Treatment Of First Patients In Phase I Trial Of Anti-HER2 ADC SYD985 Based On Its Proprietary Linker-Drug Platform 11/25/2014
$1 Billion Oncology Alliance Between Menarini Group & Oxford BioTherapeutics Initiates First-In-Human Study Of Enhanced Antibody For Treatment Of Acute Myeloid Leukemia 11/25/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
Admedus HPV Vaccine Heads To The Clinic 11/24/2014
OncoMed Pharmaceuticals, Inc. (OMED) Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium 11/24/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
Themis Bioscience’s Vaccine Against Chikungunya Successful In Phase 1 11/20/2014
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014
Clovis Oncology (CLVS) Release: Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-Free Survival (PFS) In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 11/19/2014
3-V Biosciences Announces Presentation Of First Human Clinical Data For Lead Oral FASN Inhibitor Candidate At European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research 2014 11/19/2014
The Lancet Neurology Publishes Prana’s Huntington Disease Trial 11/18/2014
Agios Pharmaceuticals (AGIO) Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia (AML) 11/18/2014
Canadian Institutes Of Health Research Release: Canada Begins Ebola Vaccine Trial 11/14/2014
Cell Source's Megadose Drug Combination Receives Regulatory Approval In Italy To Commence Human Clinical Trials 11/13/2014
Oncoethix Starts Phase 1b Trials Of OTX015 In The Treatment Of Advanced Solid Tumors (OTX015_107) And Glioma (OTX015_108) 11/12/2014
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye 11/10/2014
BioLineRx Ltd. Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment 11/5/2014
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014
MorEx Extends Phase I MTL-005 Radiation Enhancer Head & Neck Cancer Trial 11/3/2014
Suven Life Sciences Ltd Release: SUVN-G3031 For Cognition In Alzheimer’s Disease Commenced Phase 1 Clinical Trial In U.S.A. Under US-IND 123179 11/3/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Osteros Biomedica Announce Initiation Of A Phase I Clinical Trial 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
uniQure Release: AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data From Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate 10/27/2014
Trinity Biotech (TRIB) Temporary Suspends Meritas Troponin Trials 10/23/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/20/2014
MediGene, Inc. Announces Publication In Cancer Immunology, Immunotherapy On DC Vaccine Development For A Phase 1/2 Trial In Acute Myeloid Leukemia 10/16/2014
ActoGeniX Announces Positive Results From A Phase 1 Study Of AG014; Oral Capsule Administration Of An Anti-TNF-Alpha Antibody For The Treatment Of Inflammatory Bowel Disease 10/15/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Mali Health Workers Get Experimental GlaxoSmithKline (GSK) Ebola Vaccine 10/13/2014
Public Health Agency of Canada Release: Canadian Ebola Vaccine Trials Begin 10/13/2014
PharmaEngine, Inc. Will Join Nanobiotix' Pivotal Trial For NBTXR3 In Soft Tissue Sarcoma To Accelerate Its Development In Asia-Pacific 10/8/2014
Debiopharm Group™ Announces Progress In Phase I Single And Multiple Ascending Dose Study Of Debio 1450, Its Potent Anti-Staphylococcal Agent 10/7/2014
Novaliq GmbH Reports Positive Results From Cyclasol® (Cyclosporin Solution) Eye Drops Repeated And Ascending Dose Phase 1 Study 9/23/2014
First European Patients Enrolled In QT QT Vascular's ENDURE Trial 9/16/2014
United Therapeutics Corporation (UTHR) Advances To Second Cohort In Phase I Trial Of Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Treatment Of Pulmonary Arterial Hypertension 9/8/2014
GlaxoSmithKline (GSK)'s Ebola Vaccine To Be Tested For Safety In Humans As Early As Next Week 8/28/2014
NIH To Launch Phase I Of GlaxoSmithKline (GSK)'s Ebola Vaccine Candidate; NewLink Genetics VSV-EBOV 8/28/2014
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain 8/26/2014
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-3111 8/26/2014
Oncothyreon Inc. (ONTY)'s Lung Cancer Drug EMR 63325-009 Misses Primary Endpoint In Phase 1 Study 8/20/2014
KalVista Pharmaceuticals Announces Start Of Clinical Development For Novel Treatment For Diabetic Macular Edema 8/20/2014
Enzymotec Announces Initiation Of A Clinical Study On Autism Spectrum Disorder 8/12/2014
GlaxoSmithKline (GSK) Will Take Its Shot At Ebola Later This Year 8/12/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Last Patient Out In Phase Iia Trial For ORMD-0801 In Type 1 Diabetes 8/7/2014
FDA Modifies Tekmira (TKMR)'s TKM-Ebola Clinical Hold To Partial Hold 8/7/2014
Prothena Corporation plc Release: Initiation Of Multiple Ascending Dose Phase 1 Study Of PRX002 In Patients With Parkinson's Disease 8/1/2014
AstraZeneca PLC (AZN) Steps Up Push Into Cancer Immunotherapy, Falls Behind Rivals Such As Bristol-Myers Squibb Company (BMY), Merck & Co., Inc. (MRK), And Roche (RHHBY) 7/31/2014
AFFiRiS AG Release: First Clinical Data Of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 7/31/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 1 Study Of MVA-BN® Brachyury In Advanced Cancer 7/24/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update on TKM-Ebola Phase I Clinical Hold 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
BioLineRx Ltd. Announces Results From Phase 1/2 Study For Celiac Treatment 7/16/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
Probiodrug AG Presents Development Overview Of PQ912, Probiodrug’s QC-Inhibitor For Alzheimer’s Disease 7/10/2014
Novartis AG (NVS) Wins Breakthrough Status For New Leukemia Treatment CTL019 7/8/2014
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 For Treatment Of Autoimmune Diseases Entering Human Trials 7/3/2014
Tekmira Pharmaceuticals Corporation (TKMR) Sinks As The FDA Puts Ebola Study On Hold; Stock Down -15.54% At Market Close (July 3, 2014) 7/3/2014
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
Debiopharm Announces Initiation Of A Phase I Study Of Debio 1450, An IV/Oral Potent Antibiotic Active Against Staphylococcal Infections 6/19/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Basilea Pharmaceutica (BSLN.SW) Initiates Phase 1 Combination Study With Its Gram-Negative Antibiotic BAL30072 And Meropenem 6/12/2014
InnFocus Highlights Clinical Results At The European Glaucoma Society Congress 6/11/2014
D-Pharm Ltd.'s Anti-Epileptic Drug DP-VPA Is Granted Fast Track Status By The Chinese Food And Drug Administration (CFDA) 6/9/2014
Medgenics, Inc. Announces First Patient Implanted In Phase 1/2 Clinical Trial Of MDGN-201 (EPODURE) 6/6/2014
AstraZeneca PLC (AZN) Shows Off Its Cancer Pipeline 6/4/2014
Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study 6/2/2014
Nanobiotix Presents Successful Phase I Results For Its Lead Nanomedicine Product NBTXR3 At American Society of Clinical Oncology 6/2/2014
Scancell: Update On Phase 1/2 Clinical Trial Of SCIB1 In Stage III/IV Melanoma 6/2/2014
Dilaforette Presents Results From Exploratory Phase 1/2 Clinical Trial In Uncomplicated Malaria 5/30/2014
Benitec Limited (BLT.AX) Commences Patient Dosing With TT-034 In Patients With Hepatitis C 5/29/2014
uniQure Announces Successful Transfection Of Liver Cells With AAV5 And Strong Safety Data From Acute Intermittent Porphyria Clinical Trial 5/27/2014
Propanc Health Group Targets Cancer Patient Trials in 2015 5/19/2014
AstraZeneca PLC (AZN) Cancer Drug Coveted By Pfizer Inc. (PFE) Works In Trial 5/16/2014
Oncos Therapeutics Ltd. Demonstrates Systemic, Tumor-Specific Immune Response by Local Administration of its Lead Product ONCOS-102 5/8/2014
Xspray Microparticles AB Announces Positive Phase I Data for HyNap™ Nilotinib 5/8/2014
Covagen Initiates Phase 1b/2a Study Of Bispecific Anti-TNF/IL-17A Fynomab COVA322 5/5/2014
Promising Results In Phase 1 Trial Lead immatics biotechnologies GmbH To Continue Work On Vaccine (IMA950) For Glioblastoma 4/23/2014
Aspireo Pharmaceuticals Reports Data In Further Phase Ib Study 4/22/2014
One Of A Kind Trial To Test 14 AstraZeneca PLC (AZN), Pfizer Inc. (PFE) Drugs At The Same Time 4/18/2014
Critical Pharmaceuticals Limited, The University of Nottingham And Nottingham University Hospitals NHS Trust Starts First Phase I Clinical Trial On A Nano-Enabled Intranasal Teriparatide For The Treatment Of Osteoporosis 4/15/2014
Vectura Group plc (VEC.L): FAVOLIR Regulatory Update 4/11/2014
Prothena Corporation plc Release: First Human Dosed In Phase 1 Study Of PRX002 For Treatment Of Parkinson's Disease 4/9/2014
Newron Pharmaceuticals (NWRN) Release: New Results With NW-3509 Presented At SIRS Conference 4/8/2014
Oxford BioMedica PLC (OXB.L) Completes Patient Recruitment Into Retinostat® Phase I Trial 4/7/2014
Novartis AG (NVS) Shows Off A Strong Pipeline Of 19 New Compounds At American Association for Cancer Research 4/4/2014
Kamada Ltd. (KMDA.TA) Announces U.S. Proof-Of-Concept Study With Glassia® For Graft-Versus-Host Disease 4/3/2014
Novaliq GmbH Announces Launch Of A Phase 1 Study Following US And European Patent Approval Of Cyclasol® (Cyclosporin) Eye Drops 4/3/2014
Innate Pharma (IPH.PA ) : Start Of Cohort Expansion Of Phase I Trial With Lirilumab And Nivolumab In Selected Solid Tumors 3/31/2014
e-Therapeutics plc Reports Positive Interim Results From UK Phase Ia Trial Of ETS2101 (Dexanabinol) In A Variety Of Solid Tumours 3/31/2014
Ability Pharmaceuticals Initiates Clinical Trial With Its Dual mTORC1/C2 Inhibitor ABTL0812 In Patients With Lung And Pancreatic Cancer 3/26/2014
Scancell: 8mg Higher Dose SCIB1 Study On Track 3/21/2014
Adocia Confirms Positive Clinical Results For Its Biochaperone® Combo, A Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Lispro 3/20/2014
Hua Medicine Reports Strong Results For Early Diabetes Drug Trial 3/20/2014
GW Pharmaceuticals Provides Update on Cannabinoid Pipeline 3/17/2014
Betagenon AB: First Time In Man-AMPK Activator O304 3/10/2014
Adocia Announces Preliminary Positive Clinical Results For Its Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Analog Lispro, Biochaperone® Combo 2/27/2014
GANYMED Pharmaceuticals AG's IMAB027 Enters Phase I/II Clinical Trial For Ovarian Cancer 2/12/2014
Nanobiotix: Sees Clinical Advance In Soft Tissue Sarcoma Pilot Trial With Lead Product, NBTXR3 Market Development Plan Outlined For Earlier Potential Launch In 2016 2/11/2014
THERAVECTYS Finalizes The Recruitment Of Patients For The Phase I/II Clinical Trial Of Its Anti-HIV Therapeutic Vaccine Candidate 2/5/2014
Bionomics Limited (BMICY.PK) Release: BNC105 Phase I/II Trial Achieves A High Response Rate In Ovarian Cancer 2/3/2014
Admedus Herpes Interim Phase I Results 2/3/2014
Orion Corporation Release: The Androgen Receptor Inhibitor ODM-201 - New Insights In The Treatment Of Prostate Cancer 2/3/2014
e-Therapeutics plc Temporary Halts Recruitment Into ETS2101 Cancer Trials 1/24/2014
Pluristem Therapeutics (PSTI)' Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints 1/21/2014
Faron Pharmaceuticals Release: Promising New Treatment For Life Threatening Acute Respiratory Distress Syndrome (ARDS) 1/15/2014
Oxford BioMedica PLC (OXB.L) Announces Publication Of ProSavin® Phase I/II Study in The Lancet 1/10/2014
BrainStorm Cell Therapeutics Inc. Says Stem Cells Helped 75-Year Old Patient With ALS And MG 1/7/2014
Results Of Pluristem Therapeutics (PSTI)'s Phase 1/2 Muscle Injury Trial To Be Announced On January 21, 2014 1/6/2014
ARTES Biotechnology Release: TA101 GOCLIN European Funded Project For The Development Of An Innovative Product For The Treatment Of Rheumatoid Arthritis – 1,7M€ Total Budget 12/23/2013
Blaze Bioscience Inc. Announces Initiation Of First-In-Human Phase 1 Clinical Study Of BLZ-100 12/19/2013
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-283 12/19/2013
BioLineRx Ltd. Enters Clinic With Novel Treatment For Celiac Disease 12/19/2013
BerGenBio AS Release: Data Highlights BGB324 As A Potential Novel Treatment Option For Drug Resistant Chronic Myeloid Leukemia 12/17/2013
Drawbridge Pharmaceuticals Initiates Clinical Trial For Phaxan™ 12/16/2013
CureVac GmbH Completes Patient Recruitment For Phase 2 Clinical Trial Of Mrna-Based Prostate Cancer Treatment 12/16/2013
MorphoSys AG Announces Additional Clinical Trial of MOR208 12/10/2013
Adaptimmune Ltd. Announces Interim Results From A Phase I/II Trial Of Engineered T Cells Targeting Cancer Testis Antigens In Multiple Myeloma 12/10/2013
Summit Corporation Announces First Patient Dosed In A Phase 1b Clinical Trial Of Smt C1100 For Treatment Of Duchenne Muscular Dystrophy 12/9/2013
Rhizen Pharmaceuticals S.A. Announces Initiation Of A "First In Human" Phase-1 Trial Of RP6530, A Dual PI3K Delta/Gamma Inhibitor, In Patients With Hematological Malignancies 12/6/2013
Anti-Cancer Program Originating From Lead Discovery Center Reaches Clinical Trials 12/5/2013
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1205 12/4/2013
VBL Therapeutics Receives FDA Fast Track Designation For Lead Compound VB-111 11/27/2013
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study Of ISIS-GSK3 Rx And Earns $3 Million Milestone Payment From GlaxoSmithKline (GSK) 11/26/2013
Living Cell Technologies Ltd. Release: NTCELL Clinical Trial: Recruitment Of Further Patients Approved 11/25/2013
TopoTarget A/S Release: Final Results From CLN-14 Study In STS 11/20/2013
BioLineRx Ltd. Reports Publication In Peer Review Journal Of Positive Phase 1/2 Results In Stem Cell Mobilization For Multiple Myeloma 11/19/2013
Adocia Announces The Initiation Of A Clinical Trial On Its Combination Of The Long-Acting Insulin Glargine And A Fast-Acting Insulin Analog 11/13/2013
PROMETHERA Biosciences S.A./N.V. Successfully Enrols Twenty Patients In Its Multicentric Phase I/II Trial 11/12/2013
Gentium S.p.A. Announces Successful Completion Of Defibrotide Phase 1 Study In Japan 11/12/2013
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM) -Study Features THC and CBD as the Primary Cannabinoids 11/11/2013
FDA Grants Orphan Drug Status for PAT-SM6 11/6/2013
Swedish Orphan Biovitrum Hosts Capital Market Day Event - Announces Phase I Complement Inhibitor Programs 11/5/2013
Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis 11/4/2013
SEEK Announces Publication of HIV-v Data in Vaccine Journal 11/1/2013
CEVEC Pharma Release: Completion of a "First in Human" Clinical Phase I Study With a Therapeutic Protein Derived From CAP® Cells 11/1/2013
New Two-Hormone Roche (RHHBY) Drug Shows Promise in Diabetes, Obesity 11/1/2013
Kamada Ltd. (KMDA.TA) Reports New Data From an Extension Study of Its Phase I/II Trial With Glassia in Pediatric Patients With Type 1 Diabetes 10/31/2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women With Cervical Cancer 10/29/2013
Clovis Oncology (CLVS)'s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results 10/28/2013
Immunicum Doses the First Patient in a New Clinical Phase I/II-Study in Primary Liver Cancer 10/23/2013
Galapagos NV (GLPG.BR) Presents Superior Potentiator Series for CF 10/17/2013
Oxford BioMedica PLC (OXB.L) Receives Agreement From FDA and ANSM to Resume Recruitment Into Ocular Clinical Trials 10/17/2013
Galapagos NV (GLPG.BR) to Present Phase 1 Data on FFA2 Antagonist GLPG0974 at UEG Week in Berlin 10/16/2013
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients 10/14/2013
Sihuan Pharmaceutical Holdings Group Ltd. Approved for China Trials of Innovative Cancer Drug 10/11/2013
Karolinska Development AB: Pergamum Announces Final Data From Phase I/II Study of LL-37 in Patients With Chronic Leg Ulcers 10/10/2013
Medivir AB (MVIRb.F) Release: Positive Results From a Phase I Study With MIV-711 for the Treatment of Osteoarthritis and Other Bone Related Disorders 10/9/2013
Scancell Release: Investor Update Showcases Moditope® Platform and Updates SCIB1 Trial Progress 10/1/2013
Tesaro, Inc. Describes Initial Phase 1 Clinical Data for TSR-011 Presented at the European Cancer Congress 2013 9/30/2013
BerGenBio AS Study Published in Blood Highlights Axl Inhibition as a Novel Therapeutic Approach for Acute Myeloid Leukemia 9/30/2013
Ariad Pharmaceuticals, Inc. (ARIA) Presents Updated Phase 1/2 Data on AP26113 in Patients With Non-Small Cell Lung Cancer 9/30/2013
To-BBB technologies BV Presents Clinical Data on Lead Product 2B3-101 9/26/2013
Living Cell Technologies Ltd. Release: First-in-Man' Implant of Regenerative Cell Therapy in Parkinson's Disease 9/24/2013
Versartis, Inc. Presents Latest Positive Results From Its Pediatric Study of Long-Acting Growth Hormone Treatment at International Endocrinology Conference 9/23/2013
Skyepharma PLC (SKYEF) Release: Flutiform Trial for COPD Initiated in Europe 9/19/2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients With Anal Intraepithelial Neoplasia (AIN) 9/16/2013
Wanbang Biopharmaceuticals to Begin Clinical Trial of Fast-Acting Insulin Analogue 9/16/2013
Patrys Limited (PAB.AX) Release: PAT-SM6 Receives Orphan Drug Designation for Multiple Myeloma in Europe 9/12/2013
Dompe Announces the FDA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 9/11/2013
Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 9/10/2013
Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors 9/9/2013
Gamida Cell Ltd. Announces the Successful Transplantation of the First Patient in the Company's Phase I/II Study of NiCord® in a Single Cord Configuration 9/9/2013
ProSensa Holding N.V. Initiates First Patient Dosing in Phase I/II trial of PRO053 9/6/2013
Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment 9/6/2013
Apitope Announces Positive Results From Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis 9/3/2013
Imaxio Announces the First Human Clinical Trial Using Its Pro-Immunogenic Technology IMX313 in Tuberculosis 9/3/2013
Congenia Announces Enrollment of First Healthy Volunteer in Phase 1 Clinical Trial of GNX-5086 8/27/2013
Karolinska Development AB: Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis 8/27/2013
Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis 8/27/2013
Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR® Study in Mesothelioma 8/26/2013
Patrys Limited (PAB.AX) Release: Data From 2nd and 3rd Cohorts of Patients in Multiple Myeloma Clinical Trial 8/13/2013
Trophos Completes Patient Enrolment in a First Study of Olesoxime in Relapsing Remitting Multiple Sclerosis 8/7/2013
Patrys Limited (PAB.AX)'s Multiple Myeloma Clinical Trial to Progress to Final Patient Group 8/7/2013
AllaChem Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection 8/5/2013
Boehringer Ingelheim Corporation Release: First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for linagliptin in Type 2 Diabetes 7/31/2013
uniQure Announces Start of Parkinson's Disease Gene Therapy Phase I Trial by University of California, San Francisco (UCSF)/National Institutes of Health (NIH) to Test Its GDNF Gene in Patients 7/29/2013



//-->